Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer
Authors:
- 8 March 2015
- journal article
- Published by Springer Nature in Gastric Cancer
- Vol. 19 (2) , 597-606
Abstract
Weight loss during chemotherapy is a significant prognostic factor for poor survival in patients with advanced gastric cancer (AGC). However, in most studies, weight loss was measured at the end of chemotherapy, limiting its clinical use. In this study, we evaluated whether weight loss during the first month of chemotherapy could predict survival outcomes in patients with AGC. We analyzed 719 patients with metastatic or recurrent AGC who were receiving palliative chemotherapy. We calculated the initial body mass index (BMIi), percent weight loss after 1 month of chemotherapy (ΔW 1m), percent weight loss after last administration of chemotherapy (ΔW end), and average weight loss per month during chemotherapy (ΔW/m). We correlated these data with overall survival (OS) by receiver-operating characteristic (ROC) curves and Kaplan-Meier curves, and performed a subgroup analysis using Cox regression. The probabilities of longer OS had stronger correlations with ΔW/m and ΔW 1m than with ΔW end or BMIi. A significant positive correlation between ΔW 1m and ΔW/m (r 2 = 0.591, p < 0.001) was observed. Median OS of patients with ΔW 1m more than 3 % was significantly shorter than in patients with less weight loss (OS: 9.7 vs. 16.3 months, p < 0.001). Subgroup analysis revealed that ΔW 1m accompanied poor survival irrespective of other clinical characteristics. Weight loss at the very first month of palliative chemotherapy could predict unfavorable survival outcomes in AGC.Keywords
This publication has 27 references indexed in Scilit:
- Oral Nutritional Interventions in Malnourished Patients With Cancer: A Systematic Review and Meta-AnalysisJNCI: Journal of the National Cancer Institute, 2012
- Physical Exercise for Cancer Patients with Advanced Disease: A Randomized Controlled TrialThe Oncologist, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Chemotherapy for advanced gastric cancer2010
- Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinomaAnnals of Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. AdultsNew England Journal of Medicine, 2003
- Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?European Journal of Cancer, 1998
- Prognostic effect of weight loss prior tochemotherapy in cancer patientsThe American Journal of Medicine, 1980